Navigation Links
Neogen Names New Senior Science Officer; Added to S&P Index
Date:1/30/2009

LANSING, Mich., Jan. 30 /PRNewswire-FirstCall/ -- Neogen Corporation (Nasdaq: NEOG) announced the appointment of Dr. Jennifer Rice as Neogen's Senior Scientific Officer. In this newly created position, Dr. Rice will have responsibility for the overall direction of Neogen's research activities.

"Dr. Rice brings outstanding experience and educational background to this new position," said James Herbert, Neogen's chief executive officer. "She has a good understanding of opportunities for future product development and the experience of managing global programs involving large groups of scientists and multiple product activities."

Dr. Rice joins Neogen after serving in a position of Animal Health Global Product Development with Dow AgoSciences in Indianapolis where she led the program to develop and license the first plant cell produced animal vaccine, and the only such vaccine to be approved by USDA. Prior to the Dow appointment, she served as director of Research and Development for Biocor Animal Health where she was responsible for all aspects of design and development for animal vaccines and diagnostic tests. Her team was responsible for the licensure of several bovine combination vaccines.

Prior to Biocor, she spent five years with Merial in Athens, Ga., in various capacities including Director of U.S. Biological Discovery and Development. While there, her team developed and obtained a USDA approval for several vaccines for bovine, canine, and feline species. Earlier in her career, she spent time in research and research management at both Fort Dodge Animal Health and American Cyanamid. During her career, she has been closely involved with USDA approvals of several products and is listed as an inventor in numerous patents and patent applications.

Dr. Rice has also been active in several industry related groups including serving as the chairman of the Veterinary Services Committee of the Animal Health Institute.

Neogen named to S&P index

Standard & Poor's has announced that Neogen will be added to the S&P SmallCap 600 GICS Health Care Supplies Sub-Industry index after the close of trading on Monday, Feb. 2.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides. Neogen's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns.


'/>"/>
SOURCE Neogen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neogen Named Supplier of Chr. Hansen Probiotics for Swine and Poultry
2. Neogens BetaStar(R) US Dairy Antibiotic Test Approved by FDA/NCIMS
3. Neogen Reports Best Quarter in Its 26-Year History
4. Neogen Announces New Share Repurchase Program
5. NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10
6. Neogen Honored by Forbes; Two Brokerage Firms Initiate Coverage
7. Neogen Reports 26% Increase in Revenues
8. Webcast Alert: Neogen Corporation to Announce 1st Quarter Results
9. NeoGenomics Schedules its Q2 2008 Earnings Release for July 31, 2008
10. Webcast Alert: Neogen Corporation Announces Year-End Results
11. Neogen Acquires Product Line From DuPont Animal Health Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
Breaking Biology News(10 mins):